Ocrelizumab
- Ocrelizumab concentration and antidrug antibodies are associated with B-cell count in multiple sclerosis. Toorop et al., Neurol Neurosurg Psychiatry. 2023 Jan 24:jnnp-2022-330793. doi: 10.1136/jnnp-2022-330793. Epub ahead of print. PMID: 36693720.
- Ocrelizumab Concentration Is a Good Predictor of SARS-CoV-2 Vaccination Response in Patients with Multiple Sclerosis. van Kempen et al., Ann Neurol. 2023 Jan;93(1):103-108. doi: 10.1002/ana.26534. Epub 2022 Nov 2. PMID: 36250739; PMCID: PMC9874752.
